Insmed Dives 53% as Rat Data Prompt Arikace Clinical Hold
By Trista Morrison
Wednesday, August 3, 2011
Shares of Insmed Inc. dropped 52.5 percent Tuesday after data from a two-year rat carcinogenicity study prompted the FDA to slap a clinical hold on a pair of nascent Phase III trials with lung infection drug Arikace (liposomal amikacin for inhalation).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.